1.0Jordan News Gazettehttps://jordannewsgazette.comjadminhttps://jordannewsgazette.com/author/jadmin/rich600338<blockquote class="wp-embedded-content" data-secret="Fzcu20tiG0"><a href="https://jordannewsgazette.com/zenas-biopharma-announces-publication-of-phase-2-study-of-obexelimab-an-investigational-treatment-for-igg4-related-disease-igg4-rd-in-the-lancet-rheumatology/">Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://jordannewsgazette.com/zenas-biopharma-announces-publication-of-phase-2-study-of-obexelimab-an-investigational-treatment-for-igg4-related-disease-igg4-rd-in-the-lancet-rheumatology/embed/#?secret=Fzcu20tiG0" width="600" height="338" title="“Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology” — Jordan News Gazette" data-secret="Fzcu20tiG0" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); </script> Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to […]https://ci4.googleusercontent.com/proxy/uKB53apOGpq1uBFr3jL2xq7DljBlDizA8kP_bse9zMswtryZwUpX2l8-dBVZjbMcy4BP6eye74dY1mveMGaDhMjrBaEvTRVMj0LAdofMpe__k82xXJe3aXTB34HGxufcwU1IscsZGDPJvoboHBXIfm0E1QZAn7guf8S82tZ54J9VrZkJqXF7XhpOl3MHdGK_XJ_Zjw=s0-d-e1-ft#https://ml.globenewswire.com/media/MWI5YjA3YTAtZmViOC00YTczLTgyMDAtYThiMWQ3Mjk4OGI4LTEyMTkzNDg=/tiny/Zenas-BioPharma-USA-LLC.png